Search Results - "Bidoli, P." :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin

A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin

by Bossi, P., Cortinovis, D., Fatigoni, S., Cossu Rocca, M., Fabi, A., Seminara, P., Ripamonti, C., Alfieri, S., Granata, R., Bergamini, C., Agustoni, F., Bidoli, P., Nolè, F., Pessi, M.A., Macchi, F., Michellini, L., Montanaro, F., Roila, F.
Published in Annals of oncology (01.10.2017)

Get full text

Journal Article

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer

by Gerber, D.E., Horn, L., Boyer, M., Sanborn, R., Natale, R., Palmero, R., Bidoli, P., Bondarenko, I., Germonpre, P., Ghizdavescu, D., Kotsakis, A., Lena, H., Losonczy, G., Park, K., Su, W -C, Tang, M., Lai, J., Kallinteris, N.L., Shan, J.S., Reck, M., Spigel, D.R.
Published in Annals of oncology (01.07.2018)

Get full text

Journal Article

Targeted therapies and immunotherapy in non-small-cell lung cancer

Targeted therapies and immunotherapy in non-small-cell lung cancer

by Cortinovis, D, Abbate, M, Bidoli, P, Capici, S, Canova, S
Published in Ecancermedicalscience (23.06.2016)

Get full text

Journal Article

Immunotherapy in elderly patients (≥ 75 yrs) with advanced non-small cell lung cancer (NSCLC): A multicenter Italian experience

Immunotherapy in elderly patients (≥ 75 yrs) with advanced non-small cell lung cancer (NSCLC): A multicenter Italian experience

by Luciani, A., Toschi, L., Fava, S., Cortinovis, D., Filipazzi, V., Tuzi, A., Marra, A., Rossi, S., Rossi, A., Blasi, M., Violati, M., Sala, L., Agustoni, F., Bidoli, P., Zonato, S., Ferrari, D.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

$Subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase 3 study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC)$

Subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase 3 study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC)

by Reck, M., Paz-Ares, L., Pérol, M., Johnson, M., Pennell, N., Novello, S., Cappuzzo, F., Bidoli, P., Zimmermann, A., Lee, P., Sashegyi, A., Varea Menendez, R.
Published in Annals of oncology (01.10.2017)

Get full text

Journal Article

Thromboembolic risk and survival with Khorana score in resected colorectal cancer patients: Subgroup analysis from the adjuvant TOSCA trial

Thromboembolic risk and survival with Khorana score in resected colorectal cancer patients: Subgroup analysis from the adjuvant TOSCA trial

by Barni, S., Rosati, G., Zagonel, V., Pella, N., Banzi, M., Zampino, M.G., Di Bartolomeo, M., Rimassa, L., Marchetti, P., Maiello, E., Artioli, F., Ferrari, D., Labianca, R., Bidoli, P., Zaniboni, A., Sobrero, A., Iaffaioli, V., de Placido, S., Frassineti, L.G., Galli, F., Petrelli, F.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Prognostic value of neutrophil-lymphocite ratio in resected high risk colorectal cancer: An analysis of adjuvant TOSCA trial

Prognostic value of neutrophil-lymphocite ratio in resected high risk colorectal cancer: An analysis of adjuvant TOSCA trial

by Petrelli, F, Rosati, G, Banzi, M, Zampino, M G, Pella, N, Di Bartolomeo, M, Maiello, E, Bidoli, P, Ferrari, D, Rimassa, L, Labianca, R, Scartozzi, M, Lonardi, S, de Placido, S, Zaniboni, A, Sobrero, A, Frassineti, L G, Silvestris, N, Corsi, D, Galli, F, Barni, S
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Small cell lung cancer

Small cell lung cancer

by Rosti, G., Bevilacqua, G., Bidoli, P., Portalone, L., Santo, A., Genestreti, G.
Published in Annals of oncology (01.04.2006)

Get full text

Journal Article Conference Proceeding

FOLFOX4/XELOX in stage II–III colon cancer: early survival data of the Italian Three Or Six Colon Adjuvant (TOSCA) trial

FOLFOX4/XELOX in stage II–III colon cancer: early survival data of the Italian Three Or Six Colon Adjuvant (TOSCA) trial

by Zaniboni, A., Lonardi, S., Labianca, R., Di Bartolomeo, M., Rosati, G., Ronzoni, M., Pella, N., Banzi, M., Zampino, M.G., Pasini, F., Marchetti, P., Rimassa, L., Maiello, E., Bidoli, P., Cinieri, S., Barni, S., Ciuffreda, L., Beretta, G., Frontini, L., Rulli, E., Sobrero, A.
Published in Annals of oncology (01.10.2017)

Get full text

Journal Article

Metformin and risk recurrence in resected stage II/III colon cancer (CC) patients (pts): subgroup analysis from the TOSCA trial

Metformin and risk recurrence in resected stage II/III colon cancer (CC) patients (pts): subgroup analysis from the TOSCA trial

by Di Bartolomeo, M., Rosato, G., Banzi, M., Pella, N., Zampino, M.G., Rimassa, L., Maiello, E., Marchetti, P., Lonardi, S., Labianca, R., Zaniboni, A., Sobrero, A., Ferrari, D., Bidoli, P., Iaffaioli, V., De Placido, S., Frassineti, L., Frustaci, S., Nicolini, M., Vernieri, C., Galli, F.
Published in Annals of oncology (01.10.2017)

Get full text

Journal Article

Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective

Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective

by Cortinovis, D., Alberti, P., Frigeni, B., Bidoli, P., Cavaletti, G.
Published in Annals of oncology (01.05.2013)

Get full text

Journal Article

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study

by Cazzaniga, M. E., Torri, V., Villa, F., Giuntini, N., Riva, F., Zeppellini, A., Cortinovis, D., Bidoli, P.
Published in International Journal of Breast Cancer (01.01.2014)

Get full text

Journal Article

3099 Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM)

3099 Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM)

by Gregorc, V, Gaafar, R, Favaretto, A, Grossi, F, Jassem, J, Polychronis, A, Bidoli, P, Tiseo, M, O'Brien, M, Shah, R, Taylor, P, Novello, S, Muzio, A, Bearz, A, Badurak, P, Greillier, L, Fontana, F, Colombi, S, Lambiase, A, Bordignon, C
Published in European journal of cancer (1990) (01.09.2015)

Get full text

Journal Article

3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial

3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial

by Stahel, R.A, Dafni, U, Gautschi, O, Felip, E, Curioni-Fontecedro, A, Peters, S, Massutí, B, Cardenal, F, Aix, S.P, Früh, M, Pless, M, Popat, S, Kotsakis, A, Cuffe, S, Bidoli, P, Favaretto, A, Carcereny, E, Sanchez Ronco, M, Molina, M.A, Rosell, R
Published in European journal of cancer (1990) (01.09.2015)

Get full text

Journal Article

Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study

Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study

by Bidoli, P, Zilembo, N, Cortinovis, D, Mariani, L, Isa, L, Aitini, E, Cullurà, D, Pari, F, Nova, P, Mancin, M, Formisano, B, Bajetta, E
Published in Annals of oncology (01.03.2007)

Get full text

Journal Article

9007 ORAL Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients With EGFR FISH-positive Advanced NSCLC

9007 ORAL Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients With EGFR FISH-positive Advanced NSCLC

by Finocchiaro, G, Santoro, A, Grossi, F, Bidoli, P, Favaretto, A, Clementi, L, Massey, D, Lorence, R, Cappuzzo, F
Published in European journal of cancer (1990) (2011)

Get full text

Journal Article

6131 POSTER Evaluation of BRAF Mutational Status in Wild Type (WT) KRAS Metastatic Colon-Rectal Cancer (MCRC) Patients (pts) Treated With Cetuximab (C) – a Single Institution Experience

6131 POSTER Evaluation of BRAF Mutational Status in Wild Type (WT) KRAS Metastatic Colon-Rectal Cancer (MCRC) Patients (pts) Treated With Cetuximab (C) – a Single Institution Experience

by Cazzaniqa, M.E, Baronchelli, S, Bovo, G, Pellizzoni, D, Crosti, F, Giuntini, N, Villa, F, Cortinovis, D, Bidoli, P
Published in European journal of cancer (1990) (2011)

Get full text

Journal Article

FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer

FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer

by Cortinovis, D L, Andriani, F, Livio, A, Fabbri, A, Perrone, F, Marcomini, B, Pilotti, S, Mariani, L, Bidoli, P, Bajetta, E, Roz, L, Sozzi, G
Published in Current cancer drug targets (01.08.2008)

Get more information

Journal Article

Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient

Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient

by Negri, T, Casieri, P, Miselli, F, Orsenigo, M, Piacenza, C, Stacchiotti, S, Bidoli, P, Casali, P G, Pierotti, M A, Tamborini, E, Pilotti, S
Published in British journal of cancer (15.01.2007)

Get full text

Journal Article

Drugs ten years later: Epirubicin

Drugs ten years later: Epirubicin

by Bonadonna, G., Gianni, L., Santoro, A., Bonfante, V., Bidoli, P., Casali, P., Demicheli, R., Valagussa, P.
Published in Annals of oncology (01.05.1993)

Get full text

Journal Article

1
2
3
4
5
6
Next
[6]